Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C

NCT01121731 is registered in ClinicalTrials.gov with Digna Biotech S.L. as lead sponsor.

NCT NCT01121731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C
Lead sponsor
Digna Biotech S.L.
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2010
Completion date
January 31, 2013
Enrollment
70 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c virus infection, genotype 1, relapses, treatment-experienced patients